Clinical Evidence & Information

This proof-of-concept study addresses a practical gap in cardiac surgery

Fibrinogen and FXIII should be considered together as a clot-stability unit

Viscoelastometry may help guide thrombolysis decisions and bleeding-risk assessment in acute PE.

Many patients on standard dual antiplatelet therapy exhibit high on-treatment platelet reactivity (HTPR) , a risk factor for post-procedural thrombotic events.

Rapid urine DOAC screening may support thrombolysis and reversal decisions when plasma assays are slow or unavailable

ClotPro CT IN/HI ratio showed better agreement with Anti-Xa than aPTT and provides a whole-blood point-of-care UFH signal.

This case demonstrates that seizures can be triggered immediately after high-dose TXA administration

Sepsis-associated fibrinolysis resistance may be detectable using targeted fibrinolysis challenge methods.

Anti-Xa has never been validated as a UFH reference standard in CPB or ECMO, so all monitoring tools need context-specific validation.

Triple-bolus TXA reduced early postoperative bleeding versus bolus-plus-infusion without a seizure or thromboembolic signal in this cohort

TXA can be pro- or antifibrinolytic depending on plasminogen levels and timing; therapeutic co-administration with tPA produced consistent antifibrinolytic effects.

Low ML should not always be assumed to represent hyperfibrinolysis or normal fibrinolysis.